NCT04126538Unknown1 期
Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics of Single Dose
Beijing Continent Pharmaceutical Co, Ltd.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2019年8月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Urine concentration of pirfenidone
研究概览
简要总结
To evaluate the safety and pharmacokinetic characteristics of pirfenidone capsules in chronic kidney disease G2 and G3a patients, and to provide a basis for the phase II clinical trial program
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •patients with chronic kidney disease, both male and female（Patient group）;
- •18-70 years old, including 18 years old and 70 years old（Patient group）;
- •weight: male ≥50kg, female ≥45kg, 18≤BMI≤26 (BMI= weight (kg)/height 2 (m2))（Patient group）;
- •the stage of chronic kidney disease was G2 or G3a, indicating mild or moderate decrease in GFR, i.e., glomerular filtration rate was 45≤eGFR(ml/min/1.73m2) ≤89 (calculated according to ckd-epi formula)（Patient group）;
- •from 24h before the start of the study to the end of the study, subjects who agree to abstain from tobacco, alcohol, fruit juice, caffeine and tea（Patient group）;
- •I have had a detailed understanding of the nature, significance, possible benefits, possible inconvenience and potential risks of the trial before the study, and I have volunteered to participate in the clinical trial. I am able to communicate well with the investigator, comply with the requirements of the whole study, and have the ability to understand and sign the written informed consent.（Patient group）;
- •gender: Chinese healthy subjects, male and female（Control group）;
- •18-70 years old, including 18 years old and 70 years old（Control group）;
- •weight: male ≥50kg, female ≥45kg, 18≤BMI≤26 (BMI= weight (kg)/height 2 (m2))（Control group）;
- •from 24h before the start of the study to the end of the study, subjects who agree to abstain from tobacco, alcohol, fruit juice, caffeine and tea（Control group）;
- •those who have detailed understanding of the nature, significance, potential benefits, possible inconveniences and potential risks of the trial before the study, who have volunteered to participate in the clinical trial, who can communicate well with the investigator, comply with the requirements of the whole study, and who are able to understand and sign a written informed consent（Control group）;
排除标准
- •（Physician visits） have participated in any other clinical trials within the first three months of the trial（Patient group）;
- •(preliminary) of any process may affect test security, or drug in the body of the disease, not including chronic kidney disease (CKD), including but not limited to: heart, liver, gastrointestinal tract, immune system and respiratory system always or the existing system diseases (especially for any impact on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome symptoms, bowel disease or inflammatory bowel disease), active pathological bleeding (such as peptic ulcer), urticaria, eczema, dermatitis, epilepsy, allergic rhinitis, asthma, etc.)（Patient group）;
- •(consultation) allergy: if there are two or more drugs, food allergy history (including experimental drugs), lactose intolerance（Patient group）;
- •(consultation) any drugs that inhibit or induce drug metabolism in the liver (common liver enzyme inducers: barbiturates, carbamazepine, aminoximate, griseofulvin, aminopropyl, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide)（Patient group）;
- •(consultation) failure to follow a uniform diet (such as intolerance to standard meals, etc.) or difficulty swallowing（Patient group）;
- •(consultation) unable to tolerate venipuncture and/or having a history of blood or acupuncture（Patient group）;
- •(consultation) patients who have been drinking excessive amounts of tea, coffee or caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.) within 24 hours before the first administration of the drug（Patient group）;
- •(consultation) previous binge drinking (i.e., male drinking more than 28 units per week and female drinking more than 21 units per week (1 unit contains 14g alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had regularly consumed alcohol (more than 14 units per week) during the 6 months prior to the trial; Or who had taken any alcoholic product within 24 hours of initial administration（Patient group）;
- •(consultation) those who had donated blood or suffered massive bleeding (greater than 450 mL) within 3 months before the first administration of the study, or who planned to donate blood or blood components during the study period or within 3 months after the end of the study（Patient group）;
- •(consultation) acute disease during the screening phase before study or before study medication（Patient group）;
- •(consultation) patients who had taken food or drinks containing enzymes that can induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice, orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before the first administration were studied（Patient group）;
- •pregnant or lactating women, and subjects (or their partners) who have a pregnancy plan during the trial and within 3 months after the end of the study and who do not agree to use non-drug contraception during the trial（Patient group）;
- •(consultation) those who have had surgery within three months before the screening period, or who are planning to have surgery during the study period, and those who have had surgery that will affect drug absorption, distribution, metabolism and excretion（Patient group）;
- •(consultation) previous history of drug abuse or drug abuse（Patient group）;
- •(consultation) persons who have smoked more than 5 cigarettes per day in the 14 days before screening, or who cannot stop using any tobacco products during the trial（Patient group）;
- •screening for smoking or using any tobacco products up to admission（Patient group）;
- •screening phase physical examination, vital signs measurement, electrocardiogram examination, laboratory examination (hematuria routine, blood coagulation function, blood pregnancy (women of childbearing age only)) and investigator determination of clinically significant abnormalities (excluding abnormalities caused by chronic kidney disease). Abnormal liver function examination (ALT, AST, ALP, gamma GT, TP, Alb, A/G, t-bil, d-bil) suggested liver disease or liver injury. Renal function test SCr > 400 mol/L; Abnormal blood electrolyte examination (K+, Na+, Cl-, Ca2+) suggested high potassium or acidosis.（Patient group）
- •nicotine positive test（Patient group）;
- •alcohol breath test with test results greater than 0.0mg/100ml（Patient group）;
- •positive urine drug screening（Patient group）;
- •hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis spirochete antibody positive, or HIV antibody positive（Patient group）;
- •the investigator considers that there are any circumstances that may affect the subject's informed consent or adherence to the study protocol, or participation in the study may affect the study results or their own safety.（Patient group）;
- •（Physician visits）those who participated in any other clinical trials three months prior to the trial（Control group）;
- •(preliminary) of any process may affect test security, or drug in the body of the disease, including but not limited to: heart, liver, kidney, endocrine, the digestive tract, immune system and respiratory system always or the existing system diseases (especially cardiovascular diseases including cardiovascular disease risk, any impact on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome symptoms, bowel disease or inflammatory bowel disease), active pathological bleeding (such as peptic ulcer), urticaria, eczema, dermatitis, epilepsy, allergic rhinitis, asthma, etc.)（Control group）;
- •(consultation) allergy: if there are two or more drugs, food allergy history (including experimental drugs), lactose intolerance（Control group）;
- •(consultation) any drugs that inhibit or induce drug metabolism in the liver (common liver enzyme inducers: barbiturates, carbamazepine, aminoximate, griseofulvin, aminopropyl, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide); Or have used any medicines (including Chinese herbal medicines) or health supplements within 14 days prior to initial administration（Control group）;
- •(consultation) failure to follow a uniform diet (such as intolerance to standard meals, etc.) or difficulty swallowing（Control group）;
- •(consultation) unable to tolerate venipuncture and/or having a history of blood or acupuncture（Control group）;
- •(consultation) patients who have been drinking excessive amounts of tea, coffee or caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.) within 24 hours before the first administration of the drug（Control group）;
- •(consultation) previous binge drinking (i.e., male drinking more than 28 units per week and female drinking more than 21 units per week (1 unit contains 14g alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had regularly consumed alcohol (more than 14 units per week) during the 6 months prior to the trial; Or who had taken any alcoholic product within 24 hours of initial administration（Control group）;
- •(consultation) those who had donated blood or suffered massive bleeding (greater than 450 mL) within 3 months before the first administration of the study, or who planned to donate blood or blood components during the study period or within 3 months after the end of the study（Control group）;
- •(consultation) acute disease during the screening phase before study or before study medication（Control group）;
- •(consultation) patients who had taken food or drinks containing enzymes that can induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice, orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before the first administration were studied（Control group）;
- •pregnant or lactating women, and subjects (or their partners) who have a pregnancy plan during the trial and within 3 months after the end of the study and who do not agree to use non-drug contraception during the trial（Control group）;
- •(consultation) those who have had surgery within three months before the screening period, or who are planning to have surgery during the study period, and those who have had surgery that will affect drug absorption, distribution, metabolism and excretion（Control group）;
- •(consultation) previous history of drug abuse or drug abuse（Control group）;
- •(consultation) persons who have smoked more than 5 cigarettes per day in the 14 days before screening, or who cannot stop using any tobacco products during the trial（Control group）;
- •screening for smoking or using any tobacco products up to admission（Control group）;
- •screening phase physical examination, vital signs measurement, electrocardiogram examination, b-mode ultrasound examination, laboratory examination [blood routine, urine routine, blood biochemistry, blood coagulation function, blood pregnancy (women of childbearing age only)], and the investigator judged that abnormalities were clinically significant（Control group）;
- •those with positive nicotine test results（Control group）;
- •alcohol breath test with test results greater than 0.0mg/100ml（Control group）;
- •positive urine drug screening（Control group）;
- •hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis spirochete antibody positive, or HIV antibody positive（Control group）;
- •the investigator considers that there are any circumstances that may affect the subject's informed consent or adherence to the study protocol, or participation in the study may affect the study results or their own safety.（Control group）.
研究组 & 干预措施
Patient group
Experimental
Patients with chronic kidney disease take pirfenidone capsule 400mg once orally
干预措施: pirfenidone capsule (Drug)
Control group
Experimental
Healthy subjects take pirfenidone capsule 400mg once orally
干预措施: pirfenidone capsule (Drug)
结局指标
主要结局
Urine concentration of pirfenidone
时间窗: up to 24 weeks
Plasma drug concentrations of pirfenidone
时间窗: up to 24 weeks
次要结局
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(up to 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung InjuryRadiation PneumonitisNCT02296281Beijing Continent Pharmaceutical Co, Ltd.48
Unknown
4 期
Pirfenidone Effect on the Recovery of Renal Function in Septic Acute Kidney InjurySepsisAcute Kidney InjuryNCT02530359Hospital Civil de Guadalajara90
已完成
1 期
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male SubjectsPharmacokineticsNCT02957396Bayer16
已完成
1 期
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male VolunteersPharmacokineticsNCT02956109Bayer16
已完成
不适用
An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical PracticeType 2 Diabetes MellitusChronic Kidney DiseaseNCT05526157Bayer50,000